Erasca reports 44% confirmed response rate for ERAS-0015 in Phase 1 pancreatic cancer trial
ERAS•Erasca reported a 44% confirmed response rate for ERAS-0015 in a Phase 1 pancreatic cancer trial. It also outlined trial plans for pancreatic and lung cancers and reported preliminary antitumor activity for ERAS-4001.
1. Updated trial results
Erasca reported updated Phase 1 results showing tumor responses to ERAS-0015 in advanced pancreatic, lung and biliary tract cancers. Treatment was generally well tolerated, with mostly low-grade treatment-related adverse events and limited dose interruptions or reductions.
2. Trials and combination plans
A first-line pancreatic cancer Phase 3 trial was accelerated to the first half of 2027, while a potentially registration-enabling trial in previously treated lung cancer remains scheduled for then. A first-line lung cancer Phase 3 trial is planned for the second half of 2027 through the first half of 2028. Preliminary ERAS-4001 results showed antitumor activity with favorable tolerability, supporting planned combination testing with ERAS-0015 in 2027.




